Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jun;28(6):497-511.
doi: 10.1007/s40263-014-0166-2.

A Systematic Review of the Safety of Lisdexamfetamine Dimesylate

Affiliations
Free PMC article
Review

A Systematic Review of the Safety of Lisdexamfetamine Dimesylate

David R Coghill et al. CNS Drugs. .
Free PMC article

Abstract

Background: Here we review the safety and tolerability profile of lisdexamfetamine dimesylate (LDX), the first long-acting prodrug stimulant for the treatment of attention-deficit/hyperactivity disorder (ADHD).

Methods: A PubMed search was conducted for English-language articles published up to 16 September 2013 using the following search terms: (lisdexamfetamine OR lisdexamphetamine OR SPD489 OR Vyvanse OR Venvanse OR NRP104 NOT review [publication type]).

Results: In short-term, parallel-group, placebo-controlled, phase III trials, treatment-emergent adverse events (TEAEs) in children, adolescents, and adults receiving LDX were typical for those reported for stimulants in general. Decreased appetite was reported by 25-39 % of patients and insomnia by 11-19 %. The most frequently reported TEAEs in long-term studies were similar to those reported in the short-term trials. Most TEAEs were mild or moderate in severity. Literature relating to four specific safety concerns associated with stimulant medications was evaluated in detail in patients receiving LDX. Gains in weight, height, and body mass index were smaller in children and adolescents receiving LDX than in placebo controls or untreated norms. Insomnia was a frequently reported TEAE in patients with ADHD of all ages receiving LDX, although the available data indicated no overall worsening of sleep quality in adults. Post-marketing survey data suggest that the rate of non-medical use of LDX was lower than that for short-acting stimulants and lower than or equivalent to long-acting stimulant formulations. Small mean increases were seen in blood pressure and pulse rate in patients receiving LDX.

Conclusions: The safety and tolerability profile of LDX in individuals with ADHD is similar to that of other stimulants.

Figures

Fig. 1
Fig. 1
Systematic review flowchart to identify safety outcomes reported in lisdexamfetamine dimesylate clinical trials. ADHD attention-deficit/hyperactivity disorder

Similar articles

See all similar articles

Cited by 17 articles

See all "Cited by" articles

References

    1. Banaschewski T, Coghill D, Santosh P, et al. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry. 2006;15(8):476–495. doi: 10.1007/s00787-006-0549-0. - DOI - PubMed
    1. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). Canadian ADHD practice guidelines. 3rd ed. Toronto: CADDRA;2011:http://www.caddra.ca/cms4/pdfs/caddraGuidelines2011.pdf. Accessed 18 June 2013.
    1. Wolraich M, Brown L, Brown RT, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128(5):1007–1022. doi: 10.1542/peds.2011-2654. - DOI - PMC - PubMed
    1. Kooij SJ, Bejerot S, Blackwell A, et al. European consensus statement on diagnosis and treatment of adult ADHD: the European Network Adult ADHD. BMC Psychiatry. 2010;10:67. doi: 10.1186/1471-244X-10-67. - DOI - PMC - PubMed
    1. Graham J, Banaschewski T, Buitelaar J, et al. European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry. 2011;20(1):17–37. doi: 10.1007/s00787-010-0140-6. - DOI - PMC - PubMed

MeSH terms

Feedback